Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/84097
Title:
Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.
Authors:
Ranson, Malcolm R; Cheeseman, Sue; White, Shane C; Margison, Jennifer M
Abstract:
Anthracyclines are amongst the most active drugs in the treatment of breast cancer. Stealth liposomal doxorubicin (Caelyx, Doxil, Alza Pharmaceuticals Inc.) is a promising new agent under investigation for the treatment of breast cancer and other solid tumours. The liposomal encapsulation alters drug pharmacokinetics and leads to a marked change in toxicity profile compared to non-liposomal doxorubicin. The results of recently completed and ongoing clinical trials in breast cancer are reviewed.
Affiliation:
Department of Medical Oncology, Cancer Research Campaign, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M204BX, UK. malcolm.ransom@man.ac.uk
Citation:
Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. 2001, 37 (2):115-20 Crit. Rev. Oncol. Hematol.
Journal:
Critical Reviews in Oncology/Hematology
Issue Date:
Feb-2001
URI:
http://hdl.handle.net/10541/84097
PubMed ID:
11166584
Type:
Article
Language:
en
ISSN:
1040-8428
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRanson, Malcolm Ren
dc.contributor.authorCheeseman, Sueen
dc.contributor.authorWhite, Shane Cen
dc.contributor.authorMargison, Jennifer Men
dc.date.accessioned2009-10-12T16:43:56Z-
dc.date.available2009-10-12T16:43:56Z-
dc.date.issued2001-02-
dc.identifier.citationCaelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. 2001, 37 (2):115-20 Crit. Rev. Oncol. Hematol.en
dc.identifier.issn1040-8428-
dc.identifier.pmid11166584-
dc.identifier.urihttp://hdl.handle.net/10541/84097-
dc.description.abstractAnthracyclines are amongst the most active drugs in the treatment of breast cancer. Stealth liposomal doxorubicin (Caelyx, Doxil, Alza Pharmaceuticals Inc.) is a promising new agent under investigation for the treatment of breast cancer and other solid tumours. The liposomal encapsulation alters drug pharmacokinetics and leads to a marked change in toxicity profile compared to non-liposomal doxorubicin. The results of recently completed and ongoing clinical trials in breast cancer are reviewed.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBreast Neoplasms-
dc.subject.meshDoxorubicin-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLiposomes-
dc.titleCaelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Cancer Research Campaign, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M204BX, UK. malcolm.ransom@man.ac.uken
dc.identifier.journalCritical Reviews in Oncology/Hematologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.